Tagged with Clinical Trials

Saudi Arabia Dr Ahmed Alaskar is executive director of the King Abdullah International Medical Research Center (KAIMRC); president of the Saudi Society of Blood and Marrow Transplantation (SSBMT); professor of Consultant Adult Hematology & HSCT at King Saud bin Abdulaziz University for Health Sciences; and chairman of the Riyadh Global Medical Biotechnology…

Denmark Julie Enevold Brooker discusses what she sees as Janssen’s responsibility to help improve the Danish healthcare system beyond just bringing innovative medicines to patients, gives her thoughts on the new Danish National Life Science Strategy, and outlines how Danish patients could have even better access to innovation.   All stakeholders…

Denmark Spanish native Enrique Álvarez gives an overview of Denmark’s importance to Merck as a key European early launch market, a crucial clinical trial destination, and home to a treasure trove of holistic patient data. Álvarez also outlines the increasing challenges around market access in the country and his talent development…

Denmark Healthcare DENMARK is a non-profit organization and public-private partnership representing Danish healthcare stakeholders internationally. Jakob Skaarup Nielsen, its CEO, highlights the Nordic country’s “treasure trove” of health data, the efforts to digitalize even further and the population’s open mind when it comes to participating in clinical trials. Moreover, he outlines…

Saudi Arabia Clinical trials provide a pathway to innovation for clinicians and patients in countries like Saudi Arabia and form a key element of the country’s Vision 2030 national plan. As Saudi transitions away from oil towards becoming a knowledge-based economy, it is hoping to attract ever more international pharma companies to…

Turkey Dr Hamdi Akan, head of Turkey’s Clinical Research Association, dives into the country’s opportunities and barriers to become a clinical trials hub, including the world-class infrastructure and the need for a revision of the good clinical practice guidelines. Moreover, he explains why TITCK becoming an International Council for Harmonisation (ICH)…

Singapore IQVIA Biotech JAPAC’s Dr Senthil Sockalingam outlines the evolving needs of the flood of early-stage drug discovery ventures in Asia, how biotechs in the region differ from their counterparts in the US and Europe, and the most important digitalisation trends to emerge from the COVID-19 pandemic.   Almost 50 percent…

Japan Writing in the July issue of DIA’s Global Forum magazine Pfizer R&D Japan’s Atsushi Kitamura examines how both pharmaceutical companies and patients in Japan can help increase patient engagement in the clinical trial process.   Patient engagement in clinical trials in Japan has been progressing steadily in the last few…

Asia-Pacific Writing in the July issue of DIA’s Global Forum magazine Serene Ong and Gaurang Majmudar of clinical trial logistics specialists Marken outline why the shift to decentralised clinical trials brought about by COVID-19 is likely to stay in place post-pandemic.   The face of clinical trials has been changing rapidly,…

Turkey Avinash Potnis of Novartis Turkey discusses potential solutions to the country’s access and pricing dilemma which has raised concerns of system sustainability. Potnis also highlights the strengths of Turkey’s healthcare infrastructure, workforce, and the country’s prospects as a globally competitive innovation hub.   Turkey has a unique value proposition, bringing…

Denmark Ida Sofie Jensen introduces the strong fundamentals underpinning the Danish innovative life sciences industry, including governmental support for early access to medicines, a collaborative approach to pricing and reimbursement, a highly centralised hospital system, and excellent digitalised patient records. Jensen highlights that thanks to these fundamentals, Denmark is home to…

Turkey Ingrid Drechsel, head of Bayer’s pharma operations in Turkey and Iran, discusses the complexity of managing two countries under economic pressure and the advantages of Bayer’s longstanding relationship in both markets with a track record of six decades. In addition, Drechsel explains how the German company has moved from fifth…